Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
Status:
Completed
Trial end date:
2002-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may interfere with the body's ability to recognize transplanted bone
marrow cells as foreign and may help treat patients with graft-versus-host disease.
PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating
patients who have chronic graft-versus-host disease following bone marrow transplantation.